The document discusses Israel's model of biomedical innovation. It describes how Israel has achieved a high level of specialization in innovation and the relationship between physicians and the management of R&D. Key aspects of Israel's model include strong collaboration between hospitals, universities, and research institutions which helps drive medical advances. Israel also benefits from its mandatory military service, which provides leadership skills and experience that entrepreneurs can apply to starting new companies.
How Israel reimburses hospitals based on activity: the Procedure-Related Grou...OECD Governance
This presentation was made by Ruth Waitzberg, Israel, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems, held in Paris on 16-17 February 2015.
Navigating the Israeli Health Care System - March 2015Nefesh B'Nefesh
The Israeli health care system provides universal coverage to all legal residents. It is financed through taxes and administered through one of four health funds (Kupat Cholim) that are non-profit. The health funds provide a standard basket of services including primary and specialist care, hospitalization, medications, and some rehabilitative services. Supplementary private insurance can cover additional services like dental, mental health, and long term nursing care. New immigrants have immediate access to coverage without limitations. The system emphasizes preventative care through services like mother/baby clinics and relies on primary care physicians as care coordinators.
mHealth Israel_The Israeli Healthcare System_presented in English and Chinese...Levi Shapiro
Presentation by Dr. Bruce Rosen, Director, Smokler Center for Health Policy Research, in both Chinese and English, about "The Israeli Healthcare System". Includes Health System Overview, Comparative Statistics and Analysis and Vital Ingredients. Presented in Hangzhou, June, 2016; Universal insurance coverage; Financing via progressive taxation; Care provided via four health plans; Mix of hospital ownership types
Manfred 19 8-15 - israeli healthcare system - ukraineViktor Liashko
This document provides an overview of the Israeli healthcare system. It notes that healthcare is considered a fundamental human right and is provided through a universal healthcare system funded by taxes. All Israeli residents are entitled to a basic healthcare package through one of four nonprofit health funds. The health funds are responsible for providing primary care and purchasing secondary and tertiary care. The system aims to provide universal access to healthcare while controlling costs.
The impact of eHealth on Healthcare Professionals and Organisations: Health Information Management Systems in Modern Health Care. Shemer J. eHealth week 2010 (Barcelona: CCIB Convention Centre; 2010)
Israel’s Life Science Hub 2023 English Abstract.pdfLevi Shapiro
The war between Israel and Hamas brings its own set of business
challenges. Challenges that may impact how we communicate with
partners and investors abroad. We should portray the life science sector as resilient and adaptable, even in times of crisis. This document is a a messaging outline for Israel's Life Science Hub despite the war with Hamas. Four key points to emphasize:
1) Global activity (resilience and agility)
2) Continuity of care and preventive medicine
3) World leading clinical trials industry
4) Dynamic scientific, research and entrepreneurial ecosystems
The document discusses Israel's life sciences industry, with a focus on medical devices. It notes that the industry is split into two main categories: biotechnology and medical devices, with most venture capital invested in medical devices. It provides statistics on the largest medical device markets and subsectors in Israel. It also highlights that Israel has the largest number of medical device patents per capita in the world and provides a history of Israeli medical device company exits. The document discusses SCP Vitalife, an Israeli medical technology venture capital firm, and provides details on some of its active portfolio companies, including DIR Technologies, Beta-O2 Technologies, Sensible Medical Innovations, Pocared Diagnostics, and Argo Medical.
How Israel reimburses hospitals based on activity: the Procedure-Related Grou...OECD Governance
This presentation was made by Ruth Waitzberg, Israel, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems, held in Paris on 16-17 February 2015.
Navigating the Israeli Health Care System - March 2015Nefesh B'Nefesh
The Israeli health care system provides universal coverage to all legal residents. It is financed through taxes and administered through one of four health funds (Kupat Cholim) that are non-profit. The health funds provide a standard basket of services including primary and specialist care, hospitalization, medications, and some rehabilitative services. Supplementary private insurance can cover additional services like dental, mental health, and long term nursing care. New immigrants have immediate access to coverage without limitations. The system emphasizes preventative care through services like mother/baby clinics and relies on primary care physicians as care coordinators.
mHealth Israel_The Israeli Healthcare System_presented in English and Chinese...Levi Shapiro
Presentation by Dr. Bruce Rosen, Director, Smokler Center for Health Policy Research, in both Chinese and English, about "The Israeli Healthcare System". Includes Health System Overview, Comparative Statistics and Analysis and Vital Ingredients. Presented in Hangzhou, June, 2016; Universal insurance coverage; Financing via progressive taxation; Care provided via four health plans; Mix of hospital ownership types
Manfred 19 8-15 - israeli healthcare system - ukraineViktor Liashko
This document provides an overview of the Israeli healthcare system. It notes that healthcare is considered a fundamental human right and is provided through a universal healthcare system funded by taxes. All Israeli residents are entitled to a basic healthcare package through one of four nonprofit health funds. The health funds are responsible for providing primary care and purchasing secondary and tertiary care. The system aims to provide universal access to healthcare while controlling costs.
The impact of eHealth on Healthcare Professionals and Organisations: Health Information Management Systems in Modern Health Care. Shemer J. eHealth week 2010 (Barcelona: CCIB Convention Centre; 2010)
Israel’s Life Science Hub 2023 English Abstract.pdfLevi Shapiro
The war between Israel and Hamas brings its own set of business
challenges. Challenges that may impact how we communicate with
partners and investors abroad. We should portray the life science sector as resilient and adaptable, even in times of crisis. This document is a a messaging outline for Israel's Life Science Hub despite the war with Hamas. Four key points to emphasize:
1) Global activity (resilience and agility)
2) Continuity of care and preventive medicine
3) World leading clinical trials industry
4) Dynamic scientific, research and entrepreneurial ecosystems
The document discusses Israel's life sciences industry, with a focus on medical devices. It notes that the industry is split into two main categories: biotechnology and medical devices, with most venture capital invested in medical devices. It provides statistics on the largest medical device markets and subsectors in Israel. It also highlights that Israel has the largest number of medical device patents per capita in the world and provides a history of Israeli medical device company exits. The document discusses SCP Vitalife, an Israeli medical technology venture capital firm, and provides details on some of its active portfolio companies, including DIR Technologies, Beta-O2 Technologies, Sensible Medical Innovations, Pocared Diagnostics, and Argo Medical.
Israel has achieved significant scientific and technological innovations and accomplishments despite its small size and population. Some key points mentioned are that much of Windows operating systems, Pentium chips, and instant messaging technologies were developed in Israel. Israel also has a highly educated population and leads the world in per capita startup companies. It is a global leader in areas such as aviation security, medicine, stem cell research, and more.
Présentation des biotechnologies en Israël et du secteur médical en IsraëlFSJU AUJF
A l'occasion de la journée pays consacrée aux biotech et au médical en Israël, M. Alain Zeitoun, expert franco-israélien a présenté un aperçu du secteur et de l'expertise israélienne.
En préambule au salon MedinIsrael qui se tiendra en mars 2015 prochain à Tel Aviv, Israel.
Israel has achieved significant scientific and technological accomplishments despite its small size and population. It has developed many important computing and medical technologies, and has more high-tech companies per capita than any other country except the United States. Israel also leads in areas like renewable energy, academic research, and medicine.
Israel has achieved significant scientific and technological accomplishments despite its small size and population. It has developed many important computing technologies and leads the world in startup companies and scientific research publications per capita. Israel also has many medical innovations, such as pioneering medical devices and treatments for conditions like cancer, heart disease, and multiple sclerosis.
Slides from the first meeting of ECTTA held in Budapest. The presentation focused on the role of EUROMACS data in the expansion of knowledge on Mechanical Circulatory Support.
Meeting the mind:
The Neurotechnology revolution
A NEW ERA IN OUR UNDERSTANDING OF THE BRAIN
Throughout human history, the mind has been incomprehensible, other-worldly and beyond reach. The Bible describes all manner of thoughts and emotions but does not once mention the brain. Aristotle thought that the brain was a cooling mechanism for the blood. Centuries later, although the modern fields of biology and medicine have fundamentally transformed our understanding of the body and our ability to heal it, most scientists still think of the brain as the “final frontier” of research.
Yet now, the world had made advances in neuroscience and neurotechnology that, until recently, seemed impossible: brain-controlled prosthetics, neuroimaging technologies that can detect tiny lesions, cochlear implants that restore hearing, and others. Recent advances in science and technology will allow us to address some of mankind's greatest challenges. Imagine a world free of the heartbreak of degenerative brain diseases such as Alzheimer’s and Parkinson’s. Imagine a world we can reach into with our minds even if our bodies were sick or broken. Imagine a world where the blind can see.
That world is beginning to take shape in Israel today. Israeli companies and academics are playing a leading role in nurturing innovations across the spectrum of neuroscience and neurotechnology. These innovations will transform lives and the world we live in. Here are just some examples:
■ BrainsGate, an early stage company, is developing a novel implantable stimulation device that increases blood flow to the brain, significantly reducing brain damage caused by ischemic stroke
■ BrainStorm uses stem cell transplants to provide treatment for currently- incurable neurodegenerative diseases, such as Parkinson’s, ALS and conditions such as spinal cord injury
This paper elaborates on two exciting opportunities that stem from a technology platform which enables bidirectional communication between the human brain and machines: connecting the brain directly to the outside world (the Brain Machine Interface or BMI) and the development of therapeutic neurostimulation devices.
Meeting the mind: The Neurotechnology revolution - McKinsey report 2011 Israe...Dmitry Tseitlin
This document discusses the emerging field of neurotechnology and Israel's leadership role in it. It describes two major opportunities: 1) Brain-machine interfaces that can overcome physical disabilities by allowing direct communication between the brain and external devices, and 2) New therapeutic stimulation devices that can treat neurological diseases by precisely targeting the brain. The document outlines several Israeli companies and research institutions working in these areas. It argues that Israel is well-positioned to advance neurotechnology due to its strengths in technology, multidisciplinary research, and medical devices. It invites greater international collaboration to accelerate progress in developing technologies that can transform lives by meeting the mind.
Israels' Life Science IndustryThe Wealth of Innovationguestd498e
The document summarizes key facts about Israel's life science industry:
- Israel has a fast-growing and innovative life science industry, with over 1200 companies today compared to 186 in 1996.
- Israel ranks highly in scientific research and availability of new technologies. It has a highly educated workforce and strong culture of entrepreneurship.
- Major sectors include medical devices, pharmaceuticals, biotechnology, and healthcare IT. Israel is a world leader in areas like drug delivery and medical imaging.
- The government provides support through grants, incubators, and initiatives to promote commercialization of academic research.
- The life science industry has become a major driver of Israel's economy and trade, with international presence and partnerships around the world.
The document discusses Israel's life science industry and its role in addressing rising global healthcare challenges. Healthcare costs are increasing worldwide as populations age and demand better care. Israel is well-positioned to develop innovative solutions through its strong venture capital system, highly-skilled workforce, technology transfer organizations, and clusters of companies in areas like diagnostics, medical devices, and digital health. The life science industry in Israel draws on cross-sector technologies and collaborates with multinational companies to lower costs and improve care globally.
The document outlines the agenda and details of MEDinISRAEL 2015, a medical conference and exhibition taking place from March 23-26, 2015 in Tel Aviv, Israel. Key points include:
- The conference is organized by the Israel Export & International Cooperation Institute in cooperation with Israeli government ministries and will bring together over 60 countries to share knowledge and technologies.
- Presentations and panels will address current trends and challenges in healthcare delivery models, medical devices, healthcare IT, and emergency preparedness.
- The 2013 conference included 1,400 participants from over 65 countries, 45 exhibitors, and discussions of cutting-edge innovations.
- The 2015 event aims to connect global medical companies, hospitals, investors
Israel has a highly developed startup and venture capital ecosystem, with Tel Aviv ranked as the second best startup ecosystem globally. In 2014, Israeli startups raised $3.4 billion in funding, had 688 venture capital deals closed, and 18 companies went public. Israel also excels in exiting startups, with $9.8 billion raised from companies that went public and $15 billion generated from mergers and acquisitions. Factors contributing to Israel's success include heavy investment in research and development, a culture of entrepreneurship, compulsory military service that provides leadership skills, and strong support from technology incubators and university technology transfer offices.
The document summarizes the key advantages of investing in Israel's economy and business environment. It highlights Israel's highly educated workforce, culture of innovation, supportive government policies, strong high-tech sector and record of pioneering new technologies. Major international companies are said to invest heavily in R&D centers in Israel to take advantage of these conditions. Statistics are provided showing Israel's high levels of patents, venture capital investment, and foreign direct investment relative to other countries.
Israel has developed into a major startup hub due to its need for self-sufficiency in defense technologies. The government invested heavily in research and development, particularly military technologies, which led to successful civilian spin-offs and new high-tech industries. Today, Israel has one of the most innovative, technology-focused economies in the world on a per capita basis. However, Israel faces political instability, social inequality, and threats from surrounding conflicts that pose risks to continued growth and investment in its important technology sector.
Indigenous business sector trade delegation 2018Adam Levin
The document summarizes an upcoming trade delegation from Australia to Israel in October 2018 organized by the Australia Israel Chamber of Commerce (AICC) for Indigenous Business Sector and Community Leaders. The 7-day program will provide opportunities to learn about Israel's business ecosystem in industries like agri-business, health, technology, and more. Site visits are planned to companies, universities, and institutions. The total estimated cost per delegate is $11,500-$15,500 which covers most program fees and meals but not airfare, insurance, or personal expenses. Interested participants are invited to register their interest with the listed AICC contacts.
A case study on the Israeli Conceptual Abilities/Innovations by Devsena MishraDevsena Mishra
Israel is known for its innovation and technological creativity. Some areas where Israel leads in research and development include:
- Agricultural research through innovations like drip irrigation, grain storage cocoons, and biological pest control.
- Solar energy through companies developing concentrated solar power plants and research at institutions like the Ben Gurion National Solar Energy Center.
- Military engineering through technologies like the Iron Dome rocket defense system, unmanned ground vehicles, and active protection systems for vehicles.
This document provides an overview of the digital health industry in Israel. It discusses various areas within digital health including wearables like ReWalk and OrCam, eHealth/cloud computing, personalized medicine, gamification, and education. The Israeli healthcare system is also examined. Digital health is poised for significant growth in Israel given the country's leadership in innovation and its universal healthcare system which collects extensive health data that can be used to advance digital health technologies.
More than a Hundred Developments, Inventions, and Israeli Successes Galit Zamler
This presentation brings together more than a hundred developments, inventions and successes of Israelis companies. The presentation was made in honor of the Global Entrepreneurship Week in which Israeli educators schools for entrepreneurship, take part, with the encouragement of the Entrepreneurship for Kids Program, led by Galit Zamler.
During the GEW guest entrepreneurs come to schools and share their entrepreneurial process, accumulated experience, and insights.
More info on: https://www.tomorrowsuccess.com/
Medical genetics in egypt situation and perspectivesPasteur_Tunis
Présentation de Ghada El-Kamah réalisée durant le cours du réseau international des instituts Pasteur de "Médecine Génomique: du diagnostic à la thérapie " (17-21 octobre 2016)
El documento resume las últimas terapias para el tratamiento de la valvulopatía mitral, incluyendo dispositivos de anuloplastia, prótesis mitrales percutáneas y técnicas híbridas. Se describen los dispositivos comercializados con resultados modestos y seguridad aceptable. Las prótesis mitrales se encuentran en una etapa más compleja de desarrollo que la TAVI debido a la anatomía de la válvula mitral y el riesgo de daño a estructuras adyacentes como el LVOT. Los primer
El documento presenta una discusión sobre perspectivas en la investigación con productos sanitarios. Propone nuevos enfoques como la compra basada en valor que considera métricas de resultados para los pacientes. También sugiere extender modelos colaborativos entre hospitales e impulsar la implicación del sector a través de una convocatoria pública de 16 millones de euros para proyectos que promuevan la estrategia, datos, evaluación y reembolso basado en resultados. El objetivo final es tener un mayor impacto en la toma de decisiones a través de nuevas
Israel has achieved significant scientific and technological innovations and accomplishments despite its small size and population. Some key points mentioned are that much of Windows operating systems, Pentium chips, and instant messaging technologies were developed in Israel. Israel also has a highly educated population and leads the world in per capita startup companies. It is a global leader in areas such as aviation security, medicine, stem cell research, and more.
Présentation des biotechnologies en Israël et du secteur médical en IsraëlFSJU AUJF
A l'occasion de la journée pays consacrée aux biotech et au médical en Israël, M. Alain Zeitoun, expert franco-israélien a présenté un aperçu du secteur et de l'expertise israélienne.
En préambule au salon MedinIsrael qui se tiendra en mars 2015 prochain à Tel Aviv, Israel.
Israel has achieved significant scientific and technological accomplishments despite its small size and population. It has developed many important computing and medical technologies, and has more high-tech companies per capita than any other country except the United States. Israel also leads in areas like renewable energy, academic research, and medicine.
Israel has achieved significant scientific and technological accomplishments despite its small size and population. It has developed many important computing technologies and leads the world in startup companies and scientific research publications per capita. Israel also has many medical innovations, such as pioneering medical devices and treatments for conditions like cancer, heart disease, and multiple sclerosis.
Slides from the first meeting of ECTTA held in Budapest. The presentation focused on the role of EUROMACS data in the expansion of knowledge on Mechanical Circulatory Support.
Meeting the mind:
The Neurotechnology revolution
A NEW ERA IN OUR UNDERSTANDING OF THE BRAIN
Throughout human history, the mind has been incomprehensible, other-worldly and beyond reach. The Bible describes all manner of thoughts and emotions but does not once mention the brain. Aristotle thought that the brain was a cooling mechanism for the blood. Centuries later, although the modern fields of biology and medicine have fundamentally transformed our understanding of the body and our ability to heal it, most scientists still think of the brain as the “final frontier” of research.
Yet now, the world had made advances in neuroscience and neurotechnology that, until recently, seemed impossible: brain-controlled prosthetics, neuroimaging technologies that can detect tiny lesions, cochlear implants that restore hearing, and others. Recent advances in science and technology will allow us to address some of mankind's greatest challenges. Imagine a world free of the heartbreak of degenerative brain diseases such as Alzheimer’s and Parkinson’s. Imagine a world we can reach into with our minds even if our bodies were sick or broken. Imagine a world where the blind can see.
That world is beginning to take shape in Israel today. Israeli companies and academics are playing a leading role in nurturing innovations across the spectrum of neuroscience and neurotechnology. These innovations will transform lives and the world we live in. Here are just some examples:
■ BrainsGate, an early stage company, is developing a novel implantable stimulation device that increases blood flow to the brain, significantly reducing brain damage caused by ischemic stroke
■ BrainStorm uses stem cell transplants to provide treatment for currently- incurable neurodegenerative diseases, such as Parkinson’s, ALS and conditions such as spinal cord injury
This paper elaborates on two exciting opportunities that stem from a technology platform which enables bidirectional communication between the human brain and machines: connecting the brain directly to the outside world (the Brain Machine Interface or BMI) and the development of therapeutic neurostimulation devices.
Meeting the mind: The Neurotechnology revolution - McKinsey report 2011 Israe...Dmitry Tseitlin
This document discusses the emerging field of neurotechnology and Israel's leadership role in it. It describes two major opportunities: 1) Brain-machine interfaces that can overcome physical disabilities by allowing direct communication between the brain and external devices, and 2) New therapeutic stimulation devices that can treat neurological diseases by precisely targeting the brain. The document outlines several Israeli companies and research institutions working in these areas. It argues that Israel is well-positioned to advance neurotechnology due to its strengths in technology, multidisciplinary research, and medical devices. It invites greater international collaboration to accelerate progress in developing technologies that can transform lives by meeting the mind.
Israels' Life Science IndustryThe Wealth of Innovationguestd498e
The document summarizes key facts about Israel's life science industry:
- Israel has a fast-growing and innovative life science industry, with over 1200 companies today compared to 186 in 1996.
- Israel ranks highly in scientific research and availability of new technologies. It has a highly educated workforce and strong culture of entrepreneurship.
- Major sectors include medical devices, pharmaceuticals, biotechnology, and healthcare IT. Israel is a world leader in areas like drug delivery and medical imaging.
- The government provides support through grants, incubators, and initiatives to promote commercialization of academic research.
- The life science industry has become a major driver of Israel's economy and trade, with international presence and partnerships around the world.
The document discusses Israel's life science industry and its role in addressing rising global healthcare challenges. Healthcare costs are increasing worldwide as populations age and demand better care. Israel is well-positioned to develop innovative solutions through its strong venture capital system, highly-skilled workforce, technology transfer organizations, and clusters of companies in areas like diagnostics, medical devices, and digital health. The life science industry in Israel draws on cross-sector technologies and collaborates with multinational companies to lower costs and improve care globally.
The document outlines the agenda and details of MEDinISRAEL 2015, a medical conference and exhibition taking place from March 23-26, 2015 in Tel Aviv, Israel. Key points include:
- The conference is organized by the Israel Export & International Cooperation Institute in cooperation with Israeli government ministries and will bring together over 60 countries to share knowledge and technologies.
- Presentations and panels will address current trends and challenges in healthcare delivery models, medical devices, healthcare IT, and emergency preparedness.
- The 2013 conference included 1,400 participants from over 65 countries, 45 exhibitors, and discussions of cutting-edge innovations.
- The 2015 event aims to connect global medical companies, hospitals, investors
Israel has a highly developed startup and venture capital ecosystem, with Tel Aviv ranked as the second best startup ecosystem globally. In 2014, Israeli startups raised $3.4 billion in funding, had 688 venture capital deals closed, and 18 companies went public. Israel also excels in exiting startups, with $9.8 billion raised from companies that went public and $15 billion generated from mergers and acquisitions. Factors contributing to Israel's success include heavy investment in research and development, a culture of entrepreneurship, compulsory military service that provides leadership skills, and strong support from technology incubators and university technology transfer offices.
The document summarizes the key advantages of investing in Israel's economy and business environment. It highlights Israel's highly educated workforce, culture of innovation, supportive government policies, strong high-tech sector and record of pioneering new technologies. Major international companies are said to invest heavily in R&D centers in Israel to take advantage of these conditions. Statistics are provided showing Israel's high levels of patents, venture capital investment, and foreign direct investment relative to other countries.
Israel has developed into a major startup hub due to its need for self-sufficiency in defense technologies. The government invested heavily in research and development, particularly military technologies, which led to successful civilian spin-offs and new high-tech industries. Today, Israel has one of the most innovative, technology-focused economies in the world on a per capita basis. However, Israel faces political instability, social inequality, and threats from surrounding conflicts that pose risks to continued growth and investment in its important technology sector.
Indigenous business sector trade delegation 2018Adam Levin
The document summarizes an upcoming trade delegation from Australia to Israel in October 2018 organized by the Australia Israel Chamber of Commerce (AICC) for Indigenous Business Sector and Community Leaders. The 7-day program will provide opportunities to learn about Israel's business ecosystem in industries like agri-business, health, technology, and more. Site visits are planned to companies, universities, and institutions. The total estimated cost per delegate is $11,500-$15,500 which covers most program fees and meals but not airfare, insurance, or personal expenses. Interested participants are invited to register their interest with the listed AICC contacts.
A case study on the Israeli Conceptual Abilities/Innovations by Devsena MishraDevsena Mishra
Israel is known for its innovation and technological creativity. Some areas where Israel leads in research and development include:
- Agricultural research through innovations like drip irrigation, grain storage cocoons, and biological pest control.
- Solar energy through companies developing concentrated solar power plants and research at institutions like the Ben Gurion National Solar Energy Center.
- Military engineering through technologies like the Iron Dome rocket defense system, unmanned ground vehicles, and active protection systems for vehicles.
This document provides an overview of the digital health industry in Israel. It discusses various areas within digital health including wearables like ReWalk and OrCam, eHealth/cloud computing, personalized medicine, gamification, and education. The Israeli healthcare system is also examined. Digital health is poised for significant growth in Israel given the country's leadership in innovation and its universal healthcare system which collects extensive health data that can be used to advance digital health technologies.
More than a Hundred Developments, Inventions, and Israeli Successes Galit Zamler
This presentation brings together more than a hundred developments, inventions and successes of Israelis companies. The presentation was made in honor of the Global Entrepreneurship Week in which Israeli educators schools for entrepreneurship, take part, with the encouragement of the Entrepreneurship for Kids Program, led by Galit Zamler.
During the GEW guest entrepreneurs come to schools and share their entrepreneurial process, accumulated experience, and insights.
More info on: https://www.tomorrowsuccess.com/
Medical genetics in egypt situation and perspectivesPasteur_Tunis
Présentation de Ghada El-Kamah réalisée durant le cours du réseau international des instituts Pasteur de "Médecine Génomique: du diagnostic à la thérapie " (17-21 octobre 2016)
El documento resume las últimas terapias para el tratamiento de la valvulopatía mitral, incluyendo dispositivos de anuloplastia, prótesis mitrales percutáneas y técnicas híbridas. Se describen los dispositivos comercializados con resultados modestos y seguridad aceptable. Las prótesis mitrales se encuentran en una etapa más compleja de desarrollo que la TAVI debido a la anatomía de la válvula mitral y el riesgo de daño a estructuras adyacentes como el LVOT. Los primer
El documento presenta una discusión sobre perspectivas en la investigación con productos sanitarios. Propone nuevos enfoques como la compra basada en valor que considera métricas de resultados para los pacientes. También sugiere extender modelos colaborativos entre hospitales e impulsar la implicación del sector a través de una convocatoria pública de 16 millones de euros para proyectos que promuevan la estrategia, datos, evaluación y reembolso basado en resultados. El objetivo final es tener un mayor impacto en la toma de decisiones a través de nuevas
Este documento resume el marco regulatorio de las investigaciones clínicas con productos sanitarios en España. Detalla las leyes y regulaciones aplicables como los Reglamentos 2017/745 y 2017/746 de la UE. Explica los procedimientos de autorización de estudios clínicos por la Agencia Española de Medicamentos, incluyendo los plazos y documentación requerida. Finalmente, resalta los principales cambios introducidos por los nuevos reglamentos de la UE respecto a los requisitos de la evaluación clínica y supervisión ética y técnica
Este documento resume varios estudios sobre el uso de TAVI en pacientes de bajo riesgo. El estudio PARTNER 3 encontró tasas similares de muerte o ictus a los 2 años entre TAVI y cirugía convencional. Los estudios EVOLUT Low Risk y SAPIEN 3 también encontraron no inferioridad de TAVI frente a cirugía en sus objetivos primarios a 1 año. Aún quedan preguntas sin resolver como la durabilidad a largo plazo de las prótesis TAVI, especialmente en pacientes jóvenes.
Este documento presenta la perspectiva de un investigador clínico y traslacional sobre tres temas principales: 1) La relevancia de los modelos animales similares al humano, 2) La importancia de la investigación clínica española a pesar de las barreras para realizar ensayos clínicos, y 3) La diferencia entre los ensayos clínicos y la vida real. El autor también discute el impacto de la investigación cardiovascular española y la creación de una nueva unidad para reforzar el liderazgo en investigación clínica.
This document discusses key factors that influence the success of medical device development programs. It notes that development time depends on how relevant the technology is to an unmet clinical need. Risk analysis is also important for determining the complexity of the development program based on the device type and intended application. Experimental data provides the foundation, so it is important to properly analyze and interpret results from pre-clinical studies to inform decisions. The document emphasizes that risk analysis, focusing on real clinical needs, and learning from pre-clinical data are essential for navigating regulatory requirements and achieving approval.
This document summarizes new developments in pharmacology for interventional cardiology. It discusses the treatment of antithrombotic therapy in patients with atrial fibrillation who have had an acute coronary syndrome or percutaneous coronary intervention. Specifically, it reviews results from the AUGUSTUS trial, which compared apixaban to vitamin K antagonists and aspirin to placebo in over 4,600 such patients. The trial found that apixaban resulted in significantly less bleeding and fewer hospitalizations compared to vitamin K antagonists, without significant differences in ischemic events. Aspirin resulted in higher bleeding risk. Given total data, the document recommends using direct oral anticoagulants over vitamin K antagonists for these patients.
This document discusses several topics in intracoronary imaging and physiology:
1. Intracoronary imaging can help optimize complex PCI procedures by aiding in calcium evaluation, bifurcation treatment, and diffuse disease. Angiography co-registration with imaging modalities improves implementation.
2. Recent imaging studies provide new insights into acute coronary syndrome pathophysiology, such as spontaneous coronary artery dissection.
3. Additional evidence demonstrates the safety of deferring revascularization in the LAD and in ACS patients using non-hyperemic indices like iFR.
4. Co-registering iFR with angiography allows physiology to guide PCI planning and treatment, not just deferral decisions
Este documento resume varias novedades en el tratamiento percutáneo de diferentes condiciones cardíacas estructurales. Se discute evidencia reciente que respalda el tratamiento percutáneo del foramen oval patente, así como nuevos dispositivos para el cierre percutáneo. También se mencionan registros sobre el cierre percutáneo de la orejuela izquierda y datos sobre ablación septal.
El documento describe el caso de un paciente de 75 años con oclusión crónica total de la arteria coronaria media que fue revascularizado mediante múltiples técnicas complejas a través de un solo acceso vascular, incluyendo el uso de colaterales homocoronarias, disección y reentrada para comunicar las luces proximal y distal. La revascularización se completó con éxito mediante la implantación de dos stents farmacológicos largos, con buen resultado angiográfico a los 6 meses de seguimiento.
Este documento describe el caso de un paciente de 69 años que ingresó en el hospital debido a un infarto agudo de miocardio. Presentaba varios factores de riesgo cardiovascular y sus arterias coronarias estaban severamente ectásicas. Se realizaron procedimientos de angioplastia y colocación de stents para tratar lesiones en la arteria circunfleja y una rama marginal.
Ticagrelor is more effective than clopidogrel at suppressing high platelet reactivity after transcatheter aortic valve implantation (TAVI). More than two thirds of patients undergoing TAVI have high platelet reactivity, and clopidogrel does not provide adequate platelet inhibition before or after the procedure in most patients. Over one third of patients who were initially responsive to clopidogrel became non-responsive in the first month after TAVI. In contrast, ticagrelor was effective at suppressing high platelet reactivity in over 90% of patients at 6 hours and 100% at 5 days after TAVI, and maintained this effect during the 3 months following the procedure, with no increase in bleeding
Este documento describe un estudio clínico que evalúa el uso de dispositivos de cierre de orejuela izquierda en pacientes con enfermedad renal crónica terminal y alto riesgo de eventos tromboembólicos. El estudio incluirá 100 pacientes con seguimiento de 2 años para evaluar eventos cardiovasculares adversos combinados como objetivo principal y seguridad como objetivos secundarios. Hasta el momento, 30 pacientes han sido incluidos en 6 centros en España.
This document summarizes recent developments in coronary intervention. It discusses newer generation drug-eluting stents (DES) with ultra-thin struts that have been shown in randomized trials to have lower target lesion failure, mortality, myocardial infarction, and stent thrombosis compared to older DES. It also summarizes the results of the RESTORE-SVD trial which found that in patients with small vessel disease, DES were superior to drug-coated balloons for reducing death or myocardial infarction at 1 year. Finally, it mentions the COACT study which found that in women with acute myocardial infarction, the use of DES during primary percutaneous coronary intervention reduced mortality at 90 days compared to plain old balloon angioplasty.
Este documento discute el uso de la TAVI (implante de válvula aórtica transcatéter) en pacientes de bajo riesgo quirúrgico. Aunque los estudios existentes muestran resultados favorables de la TAVI en este grupo, todavía quedan varias incógnitas sobre el manejo y pronóstico a largo plazo que deben resolverse antes de generalizar su uso. Se necesitan más datos para asegurar la excelencia de los resultados con la TAVI en pacientes de bajo riesgo.
Este caso clínico describe la coronariografía y angioplastia con implante de stents de un hombre de 70 años con angina de esfuerzo estable. La coronariografía mostró oclusión crónica total de la arteria circunfleja, la cual fue canalizada mediante técnica de ping pong e implante de dos stents farmacológicos solapados.
Este documento describe las actividades de un grupo de trabajo sobre TAVI sin cirugía en España. El grupo incluye varios médicos de diferentes hospitales y su objetivo es crear una base de datos de pacientes sometidos a TAVI sin cirugía y analizar los resultados. Hasta ahora han creado la base de datos, presentado resultados preliminares en 2018 y realizado una auditoría externa del 80% de los datos. Su próximo paso es preparar una publicación con los hallazgos y escribir una revisión sobre el estado actual de la intervención TAVI sin cirugía.
El documento presenta los resultados del registro español TAVI de 2018 de la Sociedad Española de Cirugía Torácica - Cardiovascular. En 2018 se registraron 8.763 procedimientos TAVI en 24 centros españoles, con un incremento de 1.692 pacientes respecto al año anterior. La vía de acceso transfemoral fue la más frecuente, seguida de la transapical y otras vías menos comunes. Los centros con mayor número de procedimientos registrados fueron el Clínico Universitario Virgen de la Victoria y el Universitario Central de Asturias.
Este documento presenta un protocolo para un registro observacional prospectivo de pacientes con tromboembolia pulmonar (TEP) de moderado a alto riesgo. El objetivo principal es evaluar la supervivencia, la clase funcional y la calidad de vida a los 3 meses entre pacientes tratados con intervencionismo versus tratamiento médico. Se invitará a más de 10 centros hospitalarios a incluir al menos 20 pacientes cada uno durante el primer año para alcanzar una muestra de más de 200 pacientes y poder publicar resultados. Ya se han incluido prospectivamente 22 pacientes en el Hospital
Este documento resume los resultados de varios estudios realizados con datos del Registro Español de Mitraclip. El registro incluye 747 pacientes tratados con Mitraclip en 18 centros españoles entre 2011 y 2019. Dos artículos se han enviado a revistas científicas reportando resultados comparativos entre la primera y segunda generación de dispositivos Mitraclip, así como resultados según la etiología de la insuficiencia mitral. El registro continúa recolectando datos y se proponen más estudios, convirtiéndose en una valiosa base de datos
More from SHCI - Sección de Hemodinámica y Cardiología Intervencionista (20)
1. Israel: Modelo de innovación biomédica
Ariel Roguin MD PhD
Head, Interventional Cardiology
Rambam Medical Center,
B. Rappaport - Faculty of Medicine
Technion - Israel Institute of Technology
Haifa 31096 ISRAEL Mobile
aroguin@technion.ac.il
4. Israel: Modelo de innovación biomédica
El modelo Israelí,
Como se trabaja allí
Como se ha llegado a conseguir ese nivel
de superespecialización en innovación,
La relación de los médicos con la gestión
de i+I+D [investigacion, desarrollo e
innovacion tecnologica]
5. 5
Israel Facts and Figures
Israel
HAIFA
Established 1948
Area: 22,072 km2
ES:504,645 km2 [X23]
Density: 387/km2
ES: 92/km2 [X4]
Population ~8 millions
ES: ~48 millions [X6]
Unemployment: 6%
ES: ~25% [X4]
GDP per capita 38,000 US$
ES: 33,000 US$
GDP growth 3.3%
ES: 2%
Natural resources. 0
Security challenges ++++
9. • No. 1 in patent / capital
• 750 life science companies
• 7.1 million people = Silicon Valley
• 20 x less investment money
• Second generation entrepreneurs
• Tenacious spirit, focus, and chaos
Israel and Innovations in Life Science
10. Major Israeli Medical Innovations
Teva Industry
• Copaxon, Azilect
Stents
• InStent, BeStent, Nir, Express,
InspireMD and more
Biosense
• Revolutionized EP
Given Imaging
• Revolutionized GI diagnosis
Ventor
• Novel Transapical Medtronic Valve
Haifa
Yokneam
11.
12. Major Israeli Medical Innovations
Multislice CT angiographay [Elscint, Picker, Marconi, Philips]
MRI imaging [GE R&D] [investigacion, desarrollo]
Echocardiography 3D and strain [GE ultasound]
Hybrid CT/SPECT [GE Nuclear]
13. Israel: Modelo de innovación biomédica
El modelo Israelí,
Como se trabaja allí
Como se ha llegado a conseguir ese nivel
de superespecialización en innovación,
La relación de los médicos con la gestión
de i+I+D [investigacion, desarrollo e
innovacion tecnologica]
14. Health System in Israel
• Medical insurance plan is obligatory.
• All entitled to basic health care as a fundamental right.
• In a survey of 48 countries in 2013, Israel's health system was ranked
fourth in the world in terms of efficiency.
15. Health System in Israel
• Medical insurance plan is obligatory.
• All entitled to basic health care as a fundamental right.
• In a survey of 48 countries in 2013, Israel's health system was ranked
fourth in the world in terms of efficiency.
• In 2011 there were 3.3 practicing physicians per 1000 population in Israel
or 25,300 practicing physicians.
• Almost all employed by the government or HMO – fixed salary!
• Five university medical schools.
• 25 General hospitals with ER [all with CCUs], in 23 cath labs with 24/7
service for Primary PCI.
16. Health System in Israel
• Medical insurance plan is obligatory.
• All entitled to basic health care as a fundamental right.
• In a survey of 48 countries in 2013, Israel's health system was ranked
fourth in the world in terms of efficiency.
• In 2011 there were 3.3 practicing physicians per 1000 population in Israel
or 25,300 practicing physicians.
• Almost all employed by the government or HMO – fixed salary!
• Five university medical schools.
• 25 General hospitals with ER [all with CCUs], in 23 cath labs with 24/7
service for Primary PCI.
• Most senior physician are also affiliated with one of the 5 universities:
Beer Sheva, Haifa [Technion], Jerusalem, Tel Aviv, Zefat [Bar Ilan].
• No protected time for academy.
17. Israel: Modelo de innovación biomédica
Ariel Roguin MD PhD
Head, Interventional Cardiology
Rambam Medical Center,
B. Rappaport - Faculty of Medicine
Technion - Israel Institute of Technology
Haifa 31096 ISRAEL
aroguin@technion.ac.il
18. 18
Maimonides / the RAMBAM
Nació en Córdoba (España), 1138 –
Médico, rabino, filósofo y teólogo judío
de al-Ándalus de la Edad Media.
Estatua de Maimónides en Córdoba, España.
20. Innovation climate in Israel
Scientists & Technicians per 10,000 Workers
140
83 80
60
55 55
45 43
33 33 32
25
0
20
40
60
80
100
120
140
Israel US Japan Germany Canada Switzerland Taiwan UK Ireland Italy Singapore Spain
21.
22.
23.
24.
25. Julio came to the US to pursue academic career.
Initial attempts- Make a stent with Radio Shack copper wire
and soldering materials.
Funds: turned down by a number of companies
Schatz and Palmaz joined entrepreneur Phillip Romano, who
provided seed money to create a company.
Up to 1986, Palmaz, Schatz, and Romano were turned down by
virtually everyone.
Vision and support came eventually through (J&J).
26. Israel: Modelo de innovación biomédica
El modelo Israelí,
Como se trabaja allí
Como se ha llegado a conseguir ese nivel
de superespecialización en innovación,
La relación de los médicos con la gestión
de i+I+D [investigacion, desarrollo e
innovacion tecnologica]
28. Money for start up medical company
University
Institution/hospital
Chief Scientist
Incubator
Venture Capital
Device Company
Private [your own]
Angel – private investor
30. Fudan 201030
30
Haifa
Tel Aviv
Universities in Israel
Beer Sheva
Technion
University of Haifa
Ben Gurion University
Tel Aviv University
Bar Ilan University
Weizmann Institute
Hebrew University
of Jerusalem
Jerusalem
Rehovot
31. Synergy for Success
Haifa Bay Area
Rambam Medical Center
Technion, Israel Institute of
Technology
University of Haifa
Rappaport Faculty of Medicine
Rappaport Institute for Medical
Research Technion
MATAM High Tech
36. Synergy for Success
Haifa Bay Area
Rambam Medical Center
Technion, Israel Institute of
Technology
Rappaport Faculty of Medicine
Rappaport Institute for Medical
Research Technion
MATAM High Tech
38. Stages in Development
◦ Founded in Haifa(1993)
◦ Idea, technology
development, preclinical
studies, Initial human
studies (1995)
◦ Private investor
◦ Acquired by J&J (1998)
500 million US$
◦ Mapping and ablation
strategies for complex
arrhythmias and AF
Shlomo Ben Haim,
Founder
42. TAVI image based analysis:
Perpendicular Projection Selection
Each point along the curve is perpendicular to the aortic
annulus direction
Minimizes errors in positioning
+ =
54. How is it that Israel:
• a country of 7.1 million people,
• only sixty years old,
• surrounded by enemies,
• in a constant state of war since its founding,
• with no natural resources
produces more start-up companies than large, peaceful, and
stable nations like Japan, China, India, Korea, Canada, and the
United Kingdom?"
55. DNA for Israel High Tech Success
• Mandatory military service
• Immigration
59. Israel Defense Forces
• Leadership and management skills at very early age
• More mature persons
• IDF culture “learn and correct”
• IDF service provides potential entrepreneurs with the opportunities
to develop a wide array of skills and contacts.
60. Israel Defense Forces
• Leadership and management skills at very early age
• More mature persons
• IDF culture “learn and correct”
• IDF service provides potential entrepreneurs with the opportunities
to develop a wide array of skills and contacts.
• responsibility in a relatively un-hierarchical environment where
creativity and intelligence are highly valued.
• IDF soldiers have minimal guidance from the top, and are expected
to improvise, even if this means breaking some rules.
• If you're a junior officer, you call your higher-ups by their first
names, and if you see them doing something wrong, you say so.
• Neither ranks nor ages matter much "when taxi drivers can
command millionaires and 23-year-olds can train their uncles.
61. Medicine Studies in Israel
Military Service -> Medicine
Medicine [atuda] -> Doctor in the army for 5
years as officer with multiple responsibilities
62. Immigration
• 9 out of 10 Jewish Israelis today are immigrants or
descendants of immigrants the first or second generation.
• Since 1990, 1 million immigrants mainly from Soviet union.
• Many hard working engineers.
• In 2014: 1 in 4 academic position speaks Russian.
• This specific demographic, causing fragmentation of
community that still continues in the country, is nevertheless
a great incentive to try their luck, to take risks because
immigrants have nothing to lose.
71. 71
Phases in Israel’s economic development
1948-1968 Agriculture
• Export mainly agriculture
•Building the science based capabilities:
- Technion 1924
- Hebrew University 1925
- Weitzman Institute 1934
•Innovations and entrepreneurship in Agriculture
(Kibbutz) and the Defense area
72. 72
Phases in Israel’s economic development
1969-1992 [Self support market]
• Arms embargo after six day war in 1967
• Army R&D and “atudaim”
• Building defense-industry-university complex
- 65% of R&D defense related
- Defense as % of GDP grew to 25% in 1980
- Indigenous industry for planes, tanks, electronics warfare
• Spin-offs from defense e.g. Elscint, Scitex, Orbitech
• Multinationals entering Israel (e.g. Intel, Motorola)
• Due to historical labor-socialist tradition deep antagonism toward
individual entrepreneurship
• Establishment of Office of Chief Scientist in 1968
73. 73
Phases in Israel’s economic development
1992-2010: take-off high-tech sector
• Yozma, a government initiative in 1993 jump-started VC
availability by leveraging (foreign) risk capital with
government investment fund
• Between 1993-2005 about 80 VC’s raised $ 13,2 bln.
• Numerous government programs to bridge gap between
ideas and first VC investment and to compensate for
market failures
74. 74
Converging factors acting as tipping point for
sustainable hi-tech growth in Israel during the 90’s
VC/PE raised in
Mln dollars
average per year
New High-Tech
Companies
average per year
77From 1969- 1992
1,214307From 1993-2005
77. KEY POINTS
• Established R&D Centers (investigacion, desarrollo)
• Venture Capital
Investments by venture capital funds constitute an added value above financial
contributions - in management, world market familiarity, strategic guidance and
economic credibility.
• Government Support of R&D Expenses
The Chief Scientist of the Ministry of Industry, Trade and Labor offers conditional
R&D grants of up to 50% of approved R&D programs. If successful the developers
are obligated to pay back royalties, up to the amount of the grant.
DNA for Israel High Tech Success
80. Government Support
• Competitive government assistance for R&D projects
• Tax holidays for up to 10 years for foreign investors
• The reform law for the Encouragement of Capital Investment
will simplify bureaucratic processes related to the approval of
investments through the establishment of a "green lane".
• In addition a "Strategic Track" will offer multinational
companies significant benefits.
81. Supportive Business Environment
• Worldwide taxation and customs treaties
• Protection of trademarks, patents and intellectual property of
all kinds
• Comprehensive legal protection of foreign companies
83. Privatization
• The privatization process began in 1986 and was
accelerated in 1997
• During this time 82 companies have ceased to
be state owned
• 2003:National airline El-Al begins privatization
• From 1986- 2002 $8.6 billion was raised through
privatization
84. Trade Agreements
• Membership in world organizations: GATT (since 1962), WTO
(since 1995) and an active part in OECD
• Israel has free trade agreements with:
EU (25) EFTA (4) Romania
US Mexico Bulgaria
Canada Turkey
85. Joint R&D Foundations
• BIRDF – with the U.S.
• USISTC – US-Israel Science and Technology Commission
• BRITECH - with Britain
• CIIRDF – with Canada
• KORIL-RDF – with Korea
• SIIRD – with Singapore
• FRANCE
• GERMANY
• ITALY
• SWEDEN
92. 92
Chief Scientist
Activities in Israel International Activities
R&D Fund Bi-National Funds
Magnet Programs U.S-Israel Science &
Technology Commission
Tnufa BI-National Agreements
Technological Incubators EUREKA
Seed Fund
European Union Programs
Office of the Chief Scientist
Generic R&D
Research Institutes Global Enterprise R&D
Cooperation
Grants: $ 400 mln; Royalty Income: $ 150 mln.
95. Incentives for R&D Centers
National Priority Zone A
National Priority Zone B
Central Israel
Tax relief program: “Cost +”
Three priority areas: A, B, C
Area C
Center of Israel
Area B
preferred regions
of Israel
Area A
most preferred
regions of Israel
2 years - tax
exemption
6 years - tax
exemption
10 years - tax
exemption
8 years – only
10% taxes
4 years – only
10% taxes
96. Grant Program Priority Zone A Priority Zone B Priority Zone C
Tax Exemption 2 Years Not Applicable Not Applicable
Reduced Company Tax
Israeli Investors 5 Years 7 Years Not Applicable
Foreign Inventors 8 Years 10 Years Not Applicable
Grant Benefit Path
Grant Rates
for Fixed Asset
Priority Zone A Priority Zone B Central Israel
Industrial Projects
(Up to 140M NIS)
24% 10%
Industrial Projects
(Above 140M NIS)
20% 10% Not Applicable
Fixed asset benefit level pending zone
Tax Benefit
97. Tax Exemption Path
Tax Program Priority Zone A Priority Zone B Priority Zone C
Tax Exemption 10 Years 6 Years 2 Years
Reduced Company Tax
Israeli Investors Not Applicable 1 Year 5 Years
Foreign Inventors Not Applicable 4 Years 8 Years
99. Tax Benefits Table (in %)
Tax Benefit Example
Not an
Approved
Enterprise
Approved Enterprise
Percent of Enterprise owned by Foreign Investors
0-49% 49-74% 74-90% 90-100%
Taxable Income 100 100 100 100 100
Company Tax 34 25 20 15 10%
Balance 66 75 80 85 90
Dividend Tax Percentage 25 25 20 15 10
Dividend Tax 16.5 11.25 12 12.75 13.5
Total Tax on Distributed
income
50.5 36.25 32 27.75 23.5
100. Fudan 2010100
100
Haifa
Herzliya
Tel Aviv
Jerusalem
Yakum
Multinationals in Israel
Rehovot
Kiryat Gat
Yokneam
Outside of healthcare, multinationals with
significant activity in Israel include:
Over 110 foreign companies have established R&D centers in
Israel, collectively employing over 35,000. Source: Invest in Israel
101. 101
Israel as R&D base
Employment in Foreign R&D Corp.
As a Share of Total Employment in R&D Companies
Source: OECD
4%
3%
5%5%5%
9%9%
6%
5%
19%
17%
15%
20%20%
44%
43%
46%
45%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
2002 2003 2004 2005 2003 2004 2002 2003 2004 2001 2002 2003 2004 2000 2001 2002 2000 2001
Israel UK Sweden Italy France Finland
102. 102
102
The Israel Case
since the 90’s growth driven by high-tech sector
University of Haifa
Tel-Aviv University
Bar-Ilan University
The Hebrew University of Jerusalem
Ben-Gurion University
Technion
Weizmann Institute of Science
100 km
• 24 incubators
• over 3000 start-ups
• over 80 VC/PE’s
• 63 companies on Nasdaq
• leading multinationals
• matured Israeli high tech
ECO system
Israel (2009)
7.4 Mln inhabitants (in 1948: 0.8 Mln)
GDP $ 204 Bln
GDP per capita
$ 27k
103. 103
The Office of the Chief Scientist Incubator program
• 28 incubators between 1990-1993 (still operating 23)
• Most incubators now privatized
• 1000 companies started in incubator and 45% after a
two years incubator period, attracted follow up financing
• The program has helped to legitimatize tech-
entrepreneurship and lowered entry barriers by
funding and managerial, expert support
104. Money for start up medical company
University
Institution/hospital
Chief Scientist
Incubator
Venture Capital
Device Company
Private [your own]
Angel – private investor
105. gMPS System
gMPS Sensor
2-D / 3-D “Map” and sensor
position
Low power
magnetic field
The MediGuide gMPS System
Technion Incubator
300 million US$ in 2008
106. Excellent Human Resources
• Highly educated workforce
• A multilingual population with cultural, historic and business
ties to almost every other nation
• Over 1 million highly educated immigrants from the former
Soviet Union since 1989
• 275 engineers per 10,000 employees
DNA for Israel High Tech Success:
107. Fudan 2010107
Human Capital -
Israel’s Biggest Asset
Percent with academic degrees (ages 25-64)
Source: the ministry of finance
0
30
60
90
120
150
0%
5%
10%
15%
20%
25%
26% in Science&Engineering
108. Excellent Human Resources II
• Well established and strong academic infrastructure
• An outstanding entrepreneurial spirit
• Success stories breed success. Everyone wants to be an
ICQ, WAZE or Medinol
• Highly trained graduates of the Israel Defense Forces have
turned cutting edge defense technology into civilian
applications.
Israel leads in encryption software, a by-product
of it’s military industry, as are so many
technologies in which it excels.
“Forbes” June 2002
DNA for Israel High Tech Success:
109. Modern Infrastructure
• State of the art telecommunications
• World renowned research and educational institutions
• A highly advanced banking and financial sector
• A large volume of high-tech and science based industry
• Early adopters of technology
DNA for Israel High Tech Success:
110. Fudan 2010110
• Informal, non-hierarchical and collectivism culture conductive to
networking
• Sense of common purpose beyond individual (company) interests
• Network spillovers from army service
• Institutionalized availability of expertise in advisory boards and coaching
• Networked infrastructure of VC,s, Angels, Corp. VC’s, Accountants,
Lawyers, etc.
• Recruitment by referrals and “friend brings friend”
Social Capital
DNA for Israel High Tech Success:
111. “YES WE CAN”
Israel entrepreneurial culture
“Donttellusitcannotbedone”
DNA for Israel High Tech Success:
112. 112
Entrepreneurship:
The Israeli context and culture
• Informality is a way of life
• Risk taking is endemic
• Three years army service (leadership, teamwork,
technology, risk-taking and improvisation); breeding
ground for entrepreneurs
• Pioneering Ethos and a sense of common purpose
• Immigrants part of the process
• International networks and experience
• Non-hierarchical society
• A real community (high collectivism)
• Building startups has become the national sport;
entrepreneurs-the new cultural heroes (legitimacy)
• Everyone questions authority
DNA for Israel High Tech Success:
115. Israel High Tech Capital Raised
• Foreign investors have considerably increased their investments in Israeli high-tech and account for a vast majority – 76% -- of capital
investment in Israeli companies.
• The majority of investments over 2013 – two-thirds – was follow-up investment, with first-time investments constituting only one-third
of the total.
• The life-science sector led funding rounds in 2013, attracting 23% of total funds raised, or $522 million. Trailing just behind it was the
software sector, which raised 21% of total capital. Both cyber security and data reached peak investment levels, as did cloud
infrastructure and big data.
116.
117.
118.
119.
120. IVC Research Center - the leading source of accurate, comprehensive, and
focused information on Israel’s high-tech industry.
122. The Concept of Remote Control Coronary
Interventions
•.
Bed Side Unit Control unit.
Remote Navigation System for Coronary Catheter based
Interventions
Patented 1998
123. First 10 patients: The Institute Cardiovascular in Fundeni hospital
Dr. Dan Delano, Bucharest, Romania
Pilot Clinical Trial
128. • 1998 First Patent filed (today, 19 granted and 38 pending)
• 2002 Company founded (TEIC, Israel)
• 2004 FIM in Romania
• 2006 Corindus Vascular Robotics founded (VC)
• 2010 CorPath 200 FIM results, Corbic Columbia
• 2011 PRECISE trial, 9 centers, 164 pts.
• 2011 Alliance with Phillips
• 2012 July, FDA clearance, Commercial installations
129. Problems in the High tech Market of Israel
• Looking for “EXITS”.
• Reach a certain level and then sell.
• Good at early stage.
• No large NOKIA etc.
130. “Rambam Health Care Campus”:
Rambam Medical Center
Rappaport School of Medicine
Rappaport Institute for Research
Technion IIT
University of Haifa
High Tech IndustryEngineers
Physicians
Scientists
Synergy for Success
133. Rambam Innovation Fund
Engineers
Physicians
Scientists
Funding
• Each year, 5 innovation grants will
be provided to physicians/
scientists with novel ideas on a
competitive basis
• The grants will fund concept
development, prototype building
and patent protection
• This will form the basis for the next
phase of development
Innovations
Engineering
Science
Medicine
134. Rambam New Campus - Building the Future
Strategic Plan
Ruth Rappaport Children’s Hospital
Biomedical Discovery Tower
Cardiovascular
Hospital
Joseph
Fishman
Emergency Department
138. The history of the manuscript began in La Coruña (Corunna), north-western Spain, in 1476 when
Isaac, son of Don Solomon de Braga commissioned a famous scribe, Moses Ibn Zabara to write
the Tenach (Old Testament) together with Rabbi David Kimchi’s (Radak) grammatical treatise
Sefer Mikhlol.
La Coruña Bible
(24th July 1476)
139. the most lavishly illuminated Hebrew Bible to survive from medieval Spain and
combines Islamic, Christian, and popular motifs
140. Small country - great spirit!
Israel has an entrepreneurial spirit
Israel has the mentality of early adopters
Israel has a creative fusion between
academy and business
Israel has a defense technology
commercialization
Israel has highly skilled workforce
Israel has a powerful VC community
Israel has investment and R&D incentives
Israel's technology advantages:
143. NEOVASC (Banai et al):
CT Angiography of Reducer in CS
Stent Induced coronary
sinus stenosis to enhance
venous perfusion and
collateralization
144. Israel’s Life Science Industry
Industry Drivers
Technology Transfer Organizations (TTOs)
Commercialized defense technology
Healthcare system
Strong entrepreneurial spirit
Powerful VC community
Highly skilled workforce
Institutional incentives
145.
146. • Get the right idea
• Secure protection, Secure initial
financing
• Product development
• Preclinical testing
• Clinical Testing
147. An enthusiastic and devoted innovator
challenged by obstacles (hospital, university.
private company, other).
148. Get the adequate financial
resources to move forward.
Can proceed in an institutional or
commercial environments.
It almost always comes with the
requirement to protect the idea
from being copied and duplicated
(patents).
149. Get the right team!
Develop the device towards first-in-man
studies
Expect a few modification based on
preclinical experience
150. Validate the technology with appropriate
in-vitro and animal models before First In
Man.
151. Proof of the technology in patients
for a specific indication.
Phases:
◦ first-in-man
◦ Intermediate size registries
◦ large scale randomized controlled clinical
trials, designed to prove safety and
efficiency.
This is where ethics and the need to
control conflicts of interest has
becomes a major consideration.
152. Compelling clinical need
Safety and efficacy
Physician training
Ease-of-use
Economic factors (reimbursement)
Commercial
Acceptance
153. Encourage industry- academia collaborations
by national programs,
Mechanisms to promote innovations-
competitive translational grants
Encourage FIM and innovative clinical studies
in Israel
◦ Shorten and simplify IRB application process
◦ Limit the time to approval
154. 154
Israel- The High-Tech Ecosystem
• Technology Hotbed (20% of Nasdaq companies Israel founded)
– Recognized as an excellent source of technology innovation
– Largest concentration of high-tech companies outside of the US
– Created category leaders in various industries
– Tremendous concentration of global technology leaders
Global
Hi-tech
Companies
Availability of
Technical
People &
Management
Expertise
Existing
Technology
Infrastructure
Experienced
2nd time
entrepreneurs
University
Computer Science
Students
Foreign
Technology
Firms
Incubators
Defense
Corporate
R&D
Leading
Academic
Institutions
& ResearchCorporate
Spin-
Offs
Seasoned VC Community
Government
Support